ListedMainboardNIDAN

Nidan Laboratories and Healthcare Limited

Nidan Laboratories and Healthcare Limited is a mainboard IPO raising ₹50 Cr at a fixed price of ₹125 a share. It listed on 12 Nov 2021 and trades at ₹13 today, −89.5% against its issue price of ₹125. It was subscribed 0.00× in total.

125
Issue price
13
Price now
−89.5%
Since issue price
12 Nov 2021
Listed on
0.00×Subscribed (final) · all exchanges

No bids yet

populated partly populated we hold nothing here — the tab says why

How its cohort has done

50 mainboard issues listed in 2021 that we can price today. This is the group this issue belongs to.

+46.0%
Median return since issue price
38%
Now trading below their issue price

Neither figure is a forecast for this issue — they describe what happened to comparable issues. Full cohort analytics →

How the book finished

The category split is the number worth reading, not the total.

QIB0.00×
Non-institutional0.00×
Retail0.00×

QIB: 0.00× their allocation. QIB: 0.00×.

See the full split, sub-category by sub-category →

What we hold for this issue

Stated up front on every issue, so a sparse page reads as a fact about the source rather than a broken one.

Category split — who bidQIB, non-institutional and retail, with sub-splits
How demand built over timeNo subscription figure was published
Price-point demand curveLive only — NSE stops serving this once bidding closes
Lead managers and registrarNot published — smaller SME issues often name none
Official documents1 document
Performance since listingComputed from our own daily closes

What happens when

28 Oct 2021Bidding opens
2 Nov 2021Bidding closes
9 Nov 2021Allotment finalised — you find out what you got
10 Nov 2021Money refunded to unsuccessful bidders
12 Nov 2021Shares list and start trading

Track NIDAN LABS AND HEALTH LTD

Results, orders, board decisions and every other filing — summarised and sent to your WhatsApp the minute they are out.

Open the company page

Figures are as published by the exchanges and the issuer’s prospectus. MarketPing publishes facts, comparisons and history only — nothing here is a recommendation to apply to this issue, and we do not publish grey market premium.